Researchers have found that Prolaris test improves health
outcomes, reduces healthcare costs and aids physicians in providing clinical
care for their patients. Prolaris test is rapidly becoming the leading
molecular prognostic test to determine if patients have aggressive prostate
cancer or not and to help physicians personalize treatment decisions.
In a study that evaluated the economic impact of the
Prolaris test, researchers have found that the test reduced costs by $2,850 per
patient tested, which over a 10-year period could save the healthcare system $6
billion. It is estimated that two-thirds of these savings would be achieved within
the first year after testing. The cost savings are possible because of active
surveillance in low and intermediate risk patients and from lower disease
progression rates in high risk patients who received more extensive treatment.
Myriad Genetics, Inc. (NASDAQ: MYGN) has announced to
present the clinical data from three studies with Prolaris in prostate cancer
patients at the 2014 Society of Urologic Oncology (SUO) Annual Meeting. They will
also present interim results from PROCEDE 1000, which is the largest
prospective clinical utility study to date that evaluates the impact of the
Prolaris test on personalizing prostate cancer treatment. Interim data analysis
of 816 patients shows that based on the results from the Prolaris test, the physicians
changed their treatment decisions in 44 percent of cases. Based on the test
score 32 percent of patients underwent a reduction in treatment, and 12 percent
of patients received more aggressive treatment.
Michael Brawer, M.D., vice president of Medical Affairs,
Myriad said, "Improving patient care is our highest priority, and we strive to
prevent the overtreatment of men with low-risk prostate cancer and the under
treatment of high-risk patients."